MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcv.2026.105938

Медицинская библиотека · Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026

Enhanced HBcAg immunoassay enables detection of clinically relevant low-level HBV viremia for treatment eligibility.

Geissler Rene, Patel Megha, Koehler Anika, Herzogenrath Joerg, Almaraz Eddie, Blumenthal Justin, Fortney Tiffany, Kumar Amit, Solbrig Todd, Diedhiou Cyrille, Mbow Moustapha, Manga Noel Magloire, Mboup Souleymane, Ahouidi Ambroise, Berg Michael, Cloherty Gavin

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Accurate staging of chronic hepatitis B is essential for guiding treatment decisions and predicting clinical outcomes. Current treatment guidelines rely on HBV DNA quantification, with therapeutic thresholds set at ≥ 2000 IU/mL or ≥ 20,000 IU/mL depending on liver enzyme levels, HBeAg status, and evidence of fibrosis or cirrhosis. Despite these guidelines, access to molecular diagnostics for HBV DNA measurement remains limited in many low- and middle-income countries (LMICs) where most infections occur, creating barriers to timely and effective care. Importantly, non-phosphorylated HBcAg, located in HBV DNA-containing particles, has emerged as surrogate biomarker for HBV DNA. However, more sensitive HBcAg immunoassays could enable detection at clinically relevant thresholds and improve disease management.

OBJECTIVE

We modified a first-generation (v1) HBcAg-specific assay by incorporating a new formulation and monoclonal antibodies, and implemented the updated assay on a digital ELISA platform (v2).

STUDY

DESIGN

HBcAg levels were analyzed in longitudinal specimens from acute HBV patients and single timepoint specimens from treatment-naïve blood donors.

RESULTS

The enhanced assay (v2) achieved a limit of quantification of 30 fg/mL, corresponding to ∼1000 HBV DNA IU/mL. Comparative analysis demonstrated a reduction in the detection threshold from 4.9 × 105 to 1000 HBV DNA IU/mL, aligning with treatment eligibility criteria. Clinical sensitivity improved on average 225-fold in patient specimens.

CONCLUSION

The HBcAg v2 assay enables detection of low viral titers consistent with treatment guidelines and correlates directly with HBV DNA levels. Its ability to specifically detect low-abundance HBcAg enhances disease staging and may support therapeutic management, particularly in resource limiting settings.

Для цитирования: Geissler Rene, Patel Megha, Koehler Anika, Herzogenrath Joerg, Almaraz Eddie, Blumenthal Justin, Fortney Tiffany, Kumar Amit, Solbrig Todd, Diedhiou Cyrille, Mbow Moustapha, Manga Noel Magloire, Mboup Souleymane, Ahouidi Ambroise, Berg Michael, Cloherty Gavin. Enhanced HBcAg immunoassay enables detection of clinically relevant low-level HBV viremia for treatment eligibility.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2026. DOI: 10.1016/j.jcv.2026.105938.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.